ArticleCureus2025
Comparison of Intraoperative Blood Loss in Patients With Benign Prostatic Hyperplasia Undergoing Bipolar Transurethral Resection of the Prostate With and Without Preoperative Oral Finasteride.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Benign prostatic hyperplasia (BPH) is a common urological condition in aging males. Transurethral resection of the prostate (TURP) is a standard modality used for the surgical management of patients with BPH. Objectives The main objective of this study is to compare the blood loss among BPH patients undergoing bipolar TURP, with and without preoperative finasteride. Methodology A comparative observational study was conducted in the Department of Urology, Sir Ganga Ram Teaching Hospital, Lahore, Pakistan, from March 2023 to August 2023. A total of 60 BPH patients were distributed into two equally sized groups. The patients in Group A were given finasteride (5.0 mg once daily) for two weeks before undergoing bipolar TURP surgery, whereas the patients in Group B underwent bipolar TURP surgery without finasteride. Intraoperative blood loss was calculated in terms of a decrease in hemoglobin (Hb) level, defined as the difference between preoperative Hb and postoperative Hb, measured 24 hours after TURP. Results Baseline variables, including mean age (64.4 ± 4.2 vs. 62.9 ± 5.2 years; p-value = 0.528), mean prostate volume (75.64 ± 12.05 vs. 69.75 ± 12.91 grams; p-value = 0.054), median BMI 23.0 (22.0-24.0) vs. 23.0 (21.0-24.0) kg/m²; p-value = 0.341, and median preoperative Hb level 14.0 (14.0-16.0) vs. 14.0 (13.0-15.0) g/dL; p-value = 0.132, were similar between the two groups. Median postoperative Hb level 14.0 (13.0-15.0) vs. 13.0 (11.0-14.0) g/dL; p-value = 0.005 was significantly different between groups. Median blood loss 0.4 (0.3-0.7) g/dL in the finasteride group was markedly lower than 1.3 (0.9-1.8) g/dL in the control group (p-value < 0.001). The need for blood transfusion, 3.6% in the finasteride group and 13.3% in the control group, was not significantly different (p-value = 0.611). Median hospital stay, 26.0 (24.0-28.0) hours in the finasteride group, was markedly shorter than 28.0 (26.0-30.0) hours in the control group (p-value = 0.011). Conclusion The study concluded that preoperative treatment with finasteride for 14 days effectively decreased intraoperative blood loss in patients with BPH who underwent bipolar TURP in our hospital. Therefore, preoperative finasteride can be used to reduce blood loss and associated complications in BPH cases scheduled for bipolar TURP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.